PDCD1 and hepatocellular carcinoma: Tang et al. recently published an article studying the combination of TACE with lenvatinib and the PD-1 inhibitor camrelizumab vs. TACE alone for its efficacy and safety in unresectable HCC with a liver function Child–Pugh grade A or B [32].